Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class III · Low risk Ongoing Initiated Mar 19, 2021 (6 years ago)

Distributed by: DocRx

Class III — Low risk. Unlikely to cause harm, but violates FDA regulations.

Why it was recalled

Labeling: Illegible label: Manufacturer received complaint of mis-alignment print of the printed dosing instructions on the blister card.

Cause type: Labeling / mix-up

Wrong label, wrong strength, mixed-up products, or packaging errors. One of the most dangerous causes - you can end up taking the wrong drug or the wrong dose. All labeling / mix-up recalls.

What was recalled

Distributed by: DocRx, Methylprednisolone Tablets, USP 4 mg, Rx, 21 Count Blister, NDC: 69306-004-21, Relabeled by: Enovachem Pharmaceuticals 379 Van Ness Ave. Suite 1403-1406, Torrance, CA 90501, Manufactured by: Jubilant Cadista Pharmaceuticals Inc. Source NDC: 59746-001-03, DocRx, Mobile, AL 36608

Affected NDCs 59746-0001-03 69306-0004-21

Compare with the code on your package — it is the most precise check available.

Drug: Methylprednisolone

Recalling firm
Asclemed USA Inc. dba Enovachem Pharmaceuticals
Origin
CA, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-0330-2021 · FDA notice

Low risk, still worth a check. Class III means the product is unlikely to cause harm but breaks an FDA rule (often labeling). If your lot matches, your pharmacy will normally swap it; there is no need for alarm.

Other Methylprednisolone recalls

See all
Class II · Moderate risk

methylprednisolone tablets

Labeling: Not Elsewhere Classified. Incorrect orientation of the blister foil applied to the blister cavities, which results in incorrect dosing information when following the directions on the foil.

Ongoing Labeling / mix-up Greenstone Llc NDC 59762-4440-2 D-0299-2026
Class III · Low risk

Methylprednisolone Acetate Injectable Suspension

Labeling: Not Elsewhere Classified; A typographical error was observed in the NDC number on the preprinted Individual Folding Cartons (secondary packaging only). Incorrect NDC Number 70121-1573-1; Correct NDC Number 70121-1574-1.

Terminated Labeling / mix-up Amneal Pharmaceuticals of New York, LLC NDC 70121-1574-01 D-0756-2023

Other recalls by Asclemed USA Inc. dba Enovachem Pharmaceuticals

All 2021 recalls
Class III · Low risk

Lidolog Kit

Labeling: Not Elsewhere Classified: The label wrap covers the barcode, making it hard to scan

Ongoing Labeling / mix-up Asclemed USA Inc. D-0713-2026
Class II · Moderate risk

Duloxetine DR Capsules

CGMP Deviations; presence of Nitrosamine Drug Substance Related Impurity (NDSRI), N-nitroso-duloxetine, above the FDA acceptable intake limit.

Ongoing Nitrosamine impurity Asclemed USA Inc. NDC 76420-634-30 D-0555-2026